Drugs / ESG401
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04892342 | Sep 2021 → Jun 2025 | breast neoplasm, colorectal neoplasm, gastric neoplasm, lung neoplasm +2 | Shanghai Escugen Biotechnology Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06145308 | Aug 2023 → Jul 2028 expected | salivary gland carcinoma | Peking Union Medical College | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06732323 | Sep 2025 → Jun 2027 expected | triple-negative breast carcinoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06383767 | Jul 2024 → Jun 2027 expected | breast cancer | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ESG401 | “ESG401 16 mg/kg IV (days 1, 8, 15, q4w)” NCT06145308 ↗ |
| Modality | Monoclonal antibody | “humanized anti-trophoblast cell-surface antigen 2 immunoglobulin G1 monoclonal antibody” PMID 40359710 ↗ May 2025 |
| Route | Intravenous | “Administered via intravenous (IV) infusion” NCT04892342 ↗ |